(Q33383268)

26 July 2017

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma (English)

1 reference

26 July 2017

1 reference

4

Robert J Motzer

1 reference

26 July 2017

Premal H Patel

1

1 reference

26 July 2017

Peggy L Senico

series ordinal

2

1 reference

26 July 2017

Rafael E Curiel

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Clinical Genitourinary Cancer

26 July 2017

1 reference

26 July 2017

7

1 reference

26 July 2017

24-27

1 reference

26 July 2017

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

26 July 2017

1 reference

Defining the role of mTOR in cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Sunitinib: from rational design to clinical efficacy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Targeting von Hippel-Lindau pathway in renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Targeted drugs for metastatic renal cell carcinoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3740755

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19213664

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3816/CGC.2009.N.004

1 reference

26 July 2017

1 reference

26 July 2017

1 reference